Shreeram Aradhye
to talk about Medical Affairs
and lorem ipsom et lorteum
Shreeram Aradhye
to talk about Medical Affairs
and lorem ipsom et lorteum
The biotech rise, fall and rebound
It has been an exciting few years for the biotech sector, but huge peaks in investment in 2021 were replaced by funding falls in Q1 of 2022. In this infographic, GOLD reflects on the evolution of the biotech sector since 2016, tracking rising revenues, investment cuts and drugs that are making it to market despite ongoing uncertainty and turbulence.
This infographic explores the biotech rise and marginal fall over the past five years, tracking revenue, funding levels and drug approvals.
GOLD investigates the acceleration in vaccine development cycles during COVID-19 and CEPIs mission to reduce a pandemic response time to only100 days.
GOLD tracks the access landscape in Latin America by examining medicine spending over the last five years and standout examples of ongoing initiatives founded by pharmaceutical companies to improve access in the region.
GOLD's infographic archive
Click the navigation arrows to scroll through each of GOLD's past infographics. Click on an infographic to expand and download.
YOU MIGHT ALSO LIKE..
R&D
Artificially intelligent drug discovery
AI is being implemented into the drug development process to free up time, money and manpower, but how can humans and computers work together?
Opinion
Embracing pharma’s digital transformation
In his first regular column for GOLD, Davidek Herron discusses digital transformation in pharma, and how the industry can pursue operational excellence.
Innovation
Is the biotech boom on thin ice?
After dizzying heights of investment during the pandemic, biotechs have observed a slump, but the future looks more promising as investors push for disruptive innovation.